ELAVL1 and glomerulosclerosis: Surprisingly, treatment with NCS not only significantly inhibited elevated HuR expression and its key downstream target Wisp1 in diabetic kidneys, but also ameliorated progressive albuminuria, podocyte injury, renal endothelial function and glomerulosclerosis, as well as related inflammatory and oxidative stress pathways.